Concepedia

Edward Lorenzana

EL

Statistics

Publications

10

Citations

2K

H-Index

10

Active since

2004

Affiliations

Novartis (Switzerland)(Current)

Novartis (United States)

Novartis Institutes for BioMedical Research

University of California, Davis

Revolution Medicines (United States)

Edward Lorenzana is an author at Novartis (Switzerland) specializing in oncology, pharmacology, and molecular oncology.

Publications per year

2004–2021

10

Publications

10

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

Hui Gao, Joshua M. Korn, Stéphane Ferretti et al. · Nature Medicine · 2015 · 1.4K citations

, , +12

CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer

Mark L. McCleland, Kathryn Mesh, Edward Lorenzana et al. · Journal of Clinical Investigation · 2016 · 231 citations · Full text

, , +17

Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth

Bianca J. Lee, Jacob A. Boyer, G. Leslie Burnett et al. · Nature Chemical Biology · 2021 · 82 citations · Full text

, , +14

Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor

Darrin D. Stuart, Nanxin Li, Daniel J. Poon et al. · Cancer Research · 2012 · 54 citations

, , +15

Differential Detection of Five Mouse-Infecting Helicobacter Species by Multiplex PCR

Sunlian Feng, Karin S. Ku, Emir Hodzic et al. · Clinical and Vaccine Immunology · 2005 · 42 citations · Full text

, , +14

1–5 of 10